Year: 2020
Type: review
Abstract: Contemporary data indicate that patients with signs and symptoms of ischaemia and non-obstructive coronary artery disease (INOCA) often have coronary microvascular dysfunction (CMD) with elevated risk for adverse outcomes. Coronary endothelial (constriction with acetylcholine) and/or microvascular (limited coronary flow reserve with adenosine) dysfunction are well-documented, and extensive non-obstructive atherosclerosis is often present. Despite these data, patients with INOCA currently remain under-treated, in part, because existing management guidelines do not address this large, mostly female population due to the absence of evidence-based data. Relatively small sample-sized, short-term pilot studies of symptomatic mostly women, with INOCA, using intense medical therapies targeting endothelial, microvascular, and/or atherosclerosis mechanisms suggest symptom, ischaemia, and coronary vascular functional improvement, however, randomized, controlled outcome trials testing treatment strategies have not been completed. We review evidence regarding CMD pharmacotherapy. Potent statins in combination with angiotensin-converting enzyme inhibitor (ACE-I) or receptor blockers if intolerant, at maximally tolerated doses appear to improve angina, stress testing, myocardial perfusion, coronary endothelial function, and microvascular function. The Coronary Microvascular Angina trial supports invasive diagnostic testing with stratified therapy as an approach to improve symptoms and quality of life. The WARRIOR trial is testing intense medical therapy of high-intensity statin, maximally tolerated ACE-I plus aspirin on longer-term outcomes to provide evidence for guidelines. Novel treatments and those under development appear promising as the basis for future trial planning.
Source: Cardiovascular Research
DOI: 10.1093/cvr/cvaa006
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: AstraZeneca, Gilead Sciences, University of Florida, Deutsches Krebsforschungszentrum, Cedars-Sinai Medical Center, Adelson Family Foundation, British Heart Foundation, Japan Heart Foundation, National Institutes of Health, Abbott Vascular, Abbott Diagnostics, Medical Research Council, Japan Society for the Promotion of Science, National Institute on Aging, National Heart, Lung, and Blood Institute, National Center for Research Resources, NIH Clinical Center, National Center for Advancing Translational Sciences
Awards: G1134269671, G1313999278, G1369121676, G1387449349, G1438650436, G1764559527, Together: Transforming and Translating Discovery to Improve Health, Behavioral Medicine and Cardiovascular Research Training, G2620772713, G276921238, G3009210321, UCLA Clinical and Translational Science Institute, G3745418417, G430456586, G4464624970, G4850166151, Cardiovascular Events in Women's Ischemia Syndrome Evaluation, G6138076438, G6621596241, G6665007911, Angiotensin and neuroimmune activation in hypertension, Women's Ischemia Syndrome Evaluation (WISE) Coronary Vascular Dysfunction, UFRCC for Cardiovascular Cell Therapy Research Network, General Clinical Research Center, CORonary MICrovascular Angina (CorMicA): A mechanistic pilot trial and nested MRI sub-study, Brain Angiotensin In Hypertensive Neurons in Culture, UFCC for Cardiovascular Cell Therapy Research Network, Cardiac Autonomic Function in Women, Antihypertensive Mechanisms of Minocycline in Resistant Hypertension: Role of the gut microbiota-brain-immune axis, G950221744
OpenAlex ID: W3008292564
